AM Rx
AM Rx offers brand and compounded GLP-1 pathways through a named clinical network. Its quarterly headline, different legal descriptions and FDA warning all warrant answers before enrollment.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
The clinical group is identified, but the seller identity and complete order terms need clarification. A low quarterly equivalent does not answer who bills, which pharmacy dispenses or how a medication change is handled.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
FDA warning letter on record: Letter 728275 · June 2026
Current terms and privacy pages identify AM Rx, LLC. FDA identifies its warning-letter recipient as FitRX, LLC doing business as AM RX. The different legal descriptions need clarification before payment. The current weight-loss page separates a cash-pay compounded semaglutide offer from insurance-dependent brand access. A tirzepatide program also appears in the terms. A prescription depends on the treating clinician rather than the platform alone.
What AM Rx prescribes, by goal
Weight
- SemaglutideFDA-approved
- Injection (compounded)Price not published
- Injection (brand)Price not published
- TirzepatideFDA-approved
- Injection (brand)Price not published
AM Rx lists insured brand injections separately from compounded semaglutide and describes a compounded tirzepatide program in its terms. The clinician should explain the exact preparation and reason for selecting it. Do not infer that a compound inherits the safety or effectiveness evaluation of an approved brand.
Who prescribes
A licensed clinician
AM Rx’s terms place medical care with Bruno Health professional association, Outlast Health or affiliated practices. That network name does not resolve which clinician will prescribe or which pharmacy will compound an order. Get those assignments and the provider’s state credentials before relying on broad clinician-access language.
The weight-loss pathway asks eligibility questions and then sends the responses to a provider. AM Rx describes messaging, refill tools and ongoing support online. The public offer does not guarantee a scheduled video consultation or a particular response interval. Its coaching description also allows coaches who are not licensed dietitians.
Are labs required?
Testing plan and charges unconfirmed
The AM Rx membership policy reserves possible diagnostic-testing charges. A standard starting panel, monitoring interval and included allowance are not specified in the reviewed weight-loss offer. Ask who orders and interprets tests, and whether they will be billed separately.
Ready to start with AM Rx?
Prices and plans are set on the seller's own site.
What it claims, and what it cites
FDA sent AM Rx a June 2026 warning letter after reviewing its website in March 2026. The agency objected to pictured labels implying that the brand compounded the medicine. It also challenged ingredient comparisons that implied FDA evaluation or approval of compounded products. The letter concerns that dated website review; no FDA closeout was confirmed.
How it bills
AM Rx’s $106 semaglutide equivalent is qualified by a quarterly purchase. The page also advertises insured brand access from $25, which depends on coverage. A regular flexible one-month cash charge remains unresolved. Membership terms separately distinguish access-only services and medication-inclusive programs. Membership cancellation starts inside the account before renewal. Current-period fees are ordinarily not prorated, and pharmacy fulfillment restricts prescription refunds. Confirm the legal billing entity as well as the payment schedule, given the different corporate names in current policies and the FDA letter.
For and against
- For: Clinical network identified
- For: Provider-review pathway described
- For: Account cancellation instructions published
- Against: Flexible monthly charge unresolved
- Against: Individual pharmacy assignment unclear
- Against: Dated FDA warning without confirmed closeout
The evidence behind what it sells
Right for
Someone who will resolve the billing entity and prescription-specific terms before considering enrollment.
Look elsewhere if
Someone accepting the $106 quarterly equivalent as a complete monthly purchase before the billing company and pharmacy are identified.
Other sellers for weight
Novi
Also prescribes Semaglutide, Tirzepatide.
BeyondMD
Also prescribes Semaglutide, Tirzepatide.
Ambiante Health & Wellness
Also prescribes Semaglutide, Tirzepatide.
AM Rx
Frequently asked questions
- Who provides medical care?
- Terms identify Bruno Health professional association, Outlast Health and affiliated practices. Ask which clinician and pharmacy will handle the actual prescription.
- Does the headline establish a monthly plan?
- No. The $106 semaglutide figure is qualified by a quarterly purchase, and the brand headline depends on insurance.
- Was the FDA matter closed?
- A closeout was not confirmed. The warning describes historical website representations and should be read with its date and precise scope.
Sources
- Current services and access claims
- Insurance-dependent brand offers and quarterly semaglutide headline
- Platform and independent clinical group terms
- Membership billing, cancellation and refund policy
- FDA warning letter 728275
See what AM Rx prescribes today
AM Rx sets its own prices, plans and the states it serves. Check them before you start.